Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-κB activity

Cancer Research

Volumn 65, Issue 24, 2005, Pages 11588-11596

  Floryk, Daniel ^a,b   Huberman, Eliezer ^a  

^a ARGONNE NATIONAL LABORATORY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4,5 TRIMETHOXYBENZOIC ACID 8 (DIETHYLAMINO)OCTYL ESTER; ALPHA2 GLYCOPROTEIN; ANDROGEN; BAY 11 082; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DECAY ACCELERATING FACTOR; GLUCOSE REGULATED PROTEIN 78; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSINATE DEHYDROGENASE INHIBITOR; KERATIN; KERATIN 17; MEMBRANE COFACTOR PROTEIN; MYCOPHENOLIC ACID; P65 IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; TRIBUTYRIN; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN;

ANDROGEN INDEPENDENT PROSTATE CANCER; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL STRAIN; CELL STRAIN PC 3; CELL VACUOLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE INDUCTION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; SECRETORY CELL; UNINDEXED SEQUENCE;

ANDROGENS; ANTIBIOTICS, ANTINEOPLASTIC; APIGENIN; APOPTOSIS; BIOLOGICAL TRANSPORT; CALCIUM CHANNEL BLOCKERS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CYTOPLASM; DRUG THERAPY, COMBINATION; GALLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MYCOPHENOLIC ACID; NEOPLASMS, HORMONE-DEPENDENT; NF-KAPPA B; PROSTATIC NEOPLASMS; TRANSFECTION; VACUOLES;

EID: 29244450493     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1831     Document Type: Article

References (35)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Leszczyniecka M, Roberts T, Dent P, et al. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 2001;90:105-56.
3. Han ZT, Zhu XX, Yang RY, et al. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci U S A 1998;95:5357-61.
4. Beedassy A, Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol 1999;26:428-38.
5. Floryk D, Tollaksen SL, Giometti CS, et al. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5′ -monophosphate dehydrogenase. Cancer Res 2004;64:9049-56.
6. Newmark HL, Young CW. Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem Suppl 1995;22:247-53.
7. Maier S, Reich E, Martin R, et al. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. Int J Cancer 2000;88:245-51.
8. Wang X, Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003;31:e154.
9. Kuo MH, Allis CD. In vivo cross-linking and immunoprecipitation for studying dynamic protein: DNA associations in a chromatin environment. Methods 1999;19:425-33.
10. Weinmann AS, Bartley SM, Zhang T, et al. Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol Cell Biol 2001;21:6820-32.
11. Guo J, Verma UN, Gaynor RB, et al. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-κB p65 subunit. Clin Cancer Res 2004;10:3333-41.
12. Rupnarain C, Dlamini Z, Naicker S, et al. Colon cancer: genomics and apoptotic events. Biol Chem 2004;385:449-64.
13. Tilley WD, Wilson CM, Marcelli M, et al. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-6.
14. Sweeney MJ. Mycophenolic acid and its mechanism of action in cancer and psoriasis. Jpn J Antibiot 1977;30 Suppl:85-92.
15. Shimizu T, Sato K, Suzuki T, et al. Induction of plasminogen activator inhibitor-2 is associated with suppression of invasive activity in TPA-mediated differentiation of human prostate cancer cells. Biochem Biophys Res Commun 2003;309:267-71.
16. Tsukita S, Furuse M. Occludin and claudins in tight-junction strands: leading or supporting players? Trends Cell Biol 1999;9:268-73.
17. Hudson DL, Guy AT, Fry P, et al. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 2001;49:271-8.
18. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer [review]. Int J Oncol 2004;25:1509-19.
19. Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21096-103.
20. 2+ antagonist, 8-(N,N-diethylamino)octyl 3, 4, 5-trimethoxybenzoate hydrochloride (TMB-8): studies in skeletal muscles. Pharmacology 1974;12:20-31.
21. Mahony D, Kalionis B, Antalis TM. Plasminogen activator inhibitor type-2 (PAI-2) gene transcription requires a novel NF-κB-like transcriptional regulatory motif. Eur J Biochem 1999;263:765-72.
22. Aggarwal S, Takada Y, Mhashilkar AM, et al. Melanoma differentiation- associated gene-7/IL-24 gene enhances NF-κB activation and suppresses apoptosis induced by TNF. J Immunol 2004;173:4368-76.
23. Domachowske JB, Bonville CA, Rosenberg HF. Cytokeratin 17 is expressed in cells infected with respiratory syncytial virus via NF-κB activation and is associated with the formation of cytopathic syncytia. J Infect Dis 2000;182:1022-8.
24. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
25. Vermes I, Haanen C, Steffens-Nakken H, et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
26. Breitman TR, Chen ZX, Takahashi N. Potential applications of cytodifferentiation therapy in hematologic malignancies. Semin Hematol 1994;31:18-25.
27. Conley BA, Egorin MJ, Tait N, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998;4:629-34.
28. Hutt-Taylor SR, Harnish D, Richardson M, et al. Sodium butyrate and a T lymphocyte cell line-derived differentiation factor induce basophilic differentiation of the human promyelocytic leukemia cell line HL-60. Blood 1988;71:209-15.
29. 6,2′-O-dibutyryladenosine-3′:5′-cyclic monophosphate on growth, differentiation and gene expression in U937 human monoblastoid cells. Biochem Int 1991;23:555-62.
30. Karasawa Y, Okisaka S. Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells. Jpn J Ophthalmol 2004;48:542-51.
31. Kim YS, Tsao D, Siddiqui B, et al. Effects of sodium butyrate and dimethylsulfoxide on biochemical properties of human colon cancer cells. Cancer 1980;45:1185-92.
32. Lian X, Yang T. Plasminogen activator inhibitor 2: expression and role in differentiation of epidermal keratinocyte. Biol Cell 2004;96:109-16.
33. Pennington KN, Taylor JA, Bren GD, et al. 1κB kinase-dependent chronic activation of NF-κB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol 2001;21:1930-41.
34. 1 arrest and maturation in U937 human myeloid leukemia cells. Cell Cycle 2003;2:467-72.
35. Andela VB, Gordon AH, Zotalis G, et al. NFκB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res 2003;575-85.